Skip to main
CANF

CANF Stock Forecast & Price Target

CANF Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Can Fite Biopharma is a clinical-stage biopharmaceutical company focused on developing small-molecule drugs targeting the A3 adenosine receptor. They have a strong pipeline with promising drugs in Phase II and III development, including Namodenoson, Piclidenoson, and CF602. The company recently announced positive Phase 2a data for Namodenoson in pancreatic cancer and plans to pursue a combination immunotherapy strategy in a Phase 2b study. This, along with confidential partnerships in place, validates the potential of their programs and could attract industry attention. With a solid financial position, including $12.8M in net cash, and a projected value of $375M, we maintain a Buy rating and increase our 12-month price target to $8.00 per ADS. Risks include commercial, clinical, regulatory, legal, intellectual property, competition, and dilution.

Bears say

Can Fite Biopharma is currently in clinical trials for its pipeline of drugs targeting the A3AR receptor which have shown encouraging survival data in pancreatic ductal adenocarcinoma (PDAC), a difficult-to-treat cancer. However, the company's financials are concerning, with a net loss of $7.6 million in the first quarter of 2021 and a significant decrease in total assets from $38.4 million in 2020 to $13.1 million in 2021. This, combined with the competitive landscape of the biopharmaceutical industry and the limited data available on Can Fite's drugs, suggests a negative outlook on the stock at this time.

CANF has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Can-Fite BioPharma Ltd. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Can-Fite BioPharma Ltd. (CANF) Forecast

Analysts have given CANF a Strong Buy based on their latest research and market trends.

According to 2 analysts, CANF has a Strong Buy consensus rating as of Aug 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Can-Fite BioPharma Ltd. (CANF)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.